Stock Analiz

Ensysce Biosciences, Inc. ENSC

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.42Market cap $8M
Open the interactive analysis →

Ensysce Biosciences, Inc. (ENSC) is a healthcare company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $6M and net income of -$91M, a net margin of -1473.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -956%.

About Ensysce Biosciences

Ensysce Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $4M in 2020 to $5M in 2025, growth of about 5.2% a year. It was profitable in 2 of the last 8 years in our data. Its share count rose by 21220% over three years (dilution for shareholders). It spends 205% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.3
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-97.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-2.8%
Revenue growth (5 yrs, per year)5.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-534.2%
ROIC (5-yr avg.)-956.3%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$6M$5M$5M$2M$3M$4M$4M——
Net income-$91M-$10M-$8M-$11M-$25M-$30M$4M-$1M$2M
Free cash flow—-$8M———————
EPS (diluted)$-2.47$-0.50$-1.43$-8.80$-261.41$-2.78$0.00$-1.18$-0.39
Net margin-1473.7%-200.8%-153.3%-476.4%-994.1%-846.4%109.7%——
ROIC—-229.8%-132.6%-1592.1%-2659.1%-168.2%—-47.2%-15.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $4.08, 876% above the current price; targets range from $2.00 to $8.25; the consensus rating is “Strong buy”; expected EPS is $-0.23 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Ensysce Biosciences pay a dividend?

Not currently.

Is Ensysce Biosciences a good stock to buy?

We do not give buy or sell advice. Ensysce Biosciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.